Core Viewpoint - The article discusses the advancements in the production of 1,3-propanediol (1,3-PDO) using engineered strains of Klebsiella pneumoniae, highlighting significant improvements in yield and efficiency through metabolic engineering and strain evolution [2][20][23]. Summary by Sections 1. Production Methodology - 1,3-PDO is a high-value fine chemical used in cosmetics, pharmaceuticals, and plastics, traditionally produced through chemical synthesis, which involves toxic substances and high pressure. Microbial fermentation has emerged as a more economical and environmentally friendly production method [2]. - The research team led by Professor Liu Liming achieved a production yield of 138.6 g/L of 1,3-PDO using the engineered strain FMME-51, with a conversion rate of 0.52 g/g, without the need for additional VB12 [2][20]. 2. Strain Optimization - Initial strain FMME-01 produced 67.2 g/L of 1,3-PDO but generated multiple by-products that reduced yield. Subsequent modifications led to strain FMME-14, which showed improved production performance [6]. - Further optimization of the cell membrane composition in strain FMME-38 resulted in a 62.5% increase in tolerance to high 1,3-PDO concentrations and a 41.2% reduction in cell death [9][10]. 3. Enhancements in Co-Factor Synthesis - The production process relies on VB12 and NADH. The integration of genes responsible for VB12 synthesis into the genome of strain FMME-48 resulted in a VB12 concentration of 50.8 μg/L and a 1,3-PDO yield of 118.3 g/L [14]. - The dynamic regulation of NADH levels was achieved through the construction of a biosensor-based system, enhancing the NADH/NAD⁺ ratio by 31.3% in strain FMME-51, leading to a 12.3% increase in 1,3-PDO yield [18][14]. 4. Process Optimization - The optimization of glycerol feeding rates and pH levels significantly improved the production performance of strain FMME-51, achieving a 1,3-PDO yield of 135.9 g/L at a pH of 6.8 [19]. - The final optimized strain FMME-51 demonstrated a production capacity of 122.7 g/L of 1,3-PDO using low-cost crude glycerol as a substrate, showcasing its industrial potential [20][23]. 5. Industrial Implications - The research indicates a significant advancement in the bioproduction of 1,3-PDO, achieving unprecedented yields and efficiencies while eliminating the need for expensive co-factors, thus reducing production costs [20][23]. - The ability of engineered strain FMME-51 to efficiently utilize crude glycerol highlights its potential for large-scale industrial applications in the production of high-value chemicals [23].

Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. is planning to issue overseas shares (H shares) and list on the Hong Kong Stock Exchange to advance its global development strategy, with a current market value of approximately 8.35 billion [1] Company Overview - Huaheng Biotechnology focuses on synthetic biology technology, specializing in the R&D, production, and sales of bio-based products, and is recognized as a national torch key high-tech enterprise [1] - The company's main products include various amino acids and bio-based chemicals, which are widely used in multiple sectors such as intermediates, animal nutrition, personal care, plant nutrition, and functional food [1] - Huaheng has become one of the leading companies in the large-scale production of small-volume amino acid products through biological manufacturing [1] Market Position - The company ranks first globally in the production and sales of alanine and valine [1] - Recent strategic expansions include investments in bio-based chemicals such as 1,3-propanediol, succinic acid, and L-malic acid, alongside investments in related startups [1] Fundraising and Projects - In June 2023, Huaheng planned to raise no more than 1.689 billion to establish production bases for bio-based succinic acid and bio-based malic acid, each with an annual capacity of 50,000 tons [1] Collaborations and Innovations - In August 2023, Huaheng and Kaifeng Fund invested a total of 20 million in Ruijia Kang, focusing on non-grain bulk alcohol acids, with some products entering the pilot testing phase [2] - In March 2024, the company’s Chifeng base successfully commenced production of 50,000 tons of bio-based 1,3-propanediol and succinic acid [2] - In July 2024, Huaheng collaborated with Donghua University to establish a joint laboratory for bio-based chemical fibers, promoting the development of the PDO-PTT industrial chain [2] Industry Initiatives - In September 2024, Huaheng led the establishment of the world's first "Bio-based Polyester Textile Industry Alliance," aiming to create a complete bio-based polyester industry chain through collaboration among various stakeholders [4]

Core Viewpoint - The Ministry of Industry and Information Technology of China has officially announced the "First Batch of Iconic Products in Biological Manufacturing," which includes 36 products, marking a significant step in technological innovation and industrial upgrading in the biological manufacturing sector [1][3]. Summary by Sections Iconic Products List - The list includes 36 companies such as: - Shoulang Biotechnology - Micro元合成 - KaiLaiYing - Qinhongdao Huaheng Biotechnology - Qilu Pharmaceutical - JinSai Pharmaceutical - And others [3][5]. Product Details - Each product listed has specific applications and innovations: - **Ethanol Clostridium Protein**: Produced from industrial waste gases, beneficial for animal feed [5]. - **Alotose**: A low-calorie sweetener produced through microbial fermentation, enhancing production efficiency [5]. - **Nakiol Injection**: A CAR-T cell therapy for treating acute lymphoblastic leukemia, showing improved safety and efficacy [5]. - **Vitamin B**: Produced via fermentation, offering higher efficiency compared to traditional extraction methods [7]. - **Recombinant Human Serum Albumin**: Produced using rice cell technology, meeting clinical needs effectively [9]. Industry Significance - The announcement reflects the government's strong emphasis on the development of the biological manufacturing industry, showcasing the potential for innovation and growth in this sector [1][3]. Upcoming Events - The "SynBioCon 2025" conference will be held from August 20-22, focusing on AI in biological manufacturing, green chemistry, and future food and agriculture [11][12].

Group 1: Policy Release - The report includes three domestic policies related to the bio-based industry [7][18]. - Key projects in the policies focus on carbon reduction and include initiatives for biodegradable polyester rubber, high-performance bio-based materials, and sustainable aviation fuel [8][19]. Group 2: Industry Dynamics - The report highlights two domestic developments in the bio-based chemicals sector, including a project for lactic acid production and the establishment of a new company for food additives [9][20]. - A total of 13 domestic developments in the bio-manufacturing sector are reported, including strategic collaborations and new project announcements [20][21]. Group 3: Capital Events - Several financing events in the bio-based sector are noted, with companies raising millions in funding for various bio-manufacturing projects [11][22]. - Notable investments include over 100 million yuan for recombinant collagen and nearly 100 million yuan for bioactive ingredients [22]. Group 4: Scientific Research Progress - Significant breakthroughs in scientific research related to bio-based materials and manufacturing are reported, including advancements in bioremediation and the synthesis of high-order carbohydrates [12][23]. - Research highlights include the development of engineered bacteria for pollutant degradation and innovative methods for synthesizing sugars from low-carbon molecules [23]. Group 5: Upcoming Events - The fourth Synthetic Biology and Green Bio-Manufacturing Conference is scheduled for August 20-22, 2025, in Jinan, Shandong, focusing on industry trends and technological innovations [25][26].